Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207036698> ?p ?o ?g. }
- W4207036698 endingPage "1857" @default.
- W4207036698 startingPage "1857" @default.
- W4207036698 abstract "Abstract Introduction: The PETAL trial is a multicenter randomized controlled study for patients with aggressive lymphomas of diverse histologies (EudraCT 2006-001641-33, NCT00554164). In the study population as a whole interim PET (iPET) reliably predicted time to treatment failure (TTTF) and overall survival (OS). Interim PET-based treatment changes, however, had no impact on outcome (ASH 2014, abstract 391). Here we report the exploratory analysis for aggressive B cell lymphomas. Methods: Pts. aged 18 to 80 yrs. with newly diagnosed aggressive lymphomas and a positive baseline PET received 2 cycles of rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) followed by iPET. The conditions of iPET were strictly defined: 3-week interval between the 2nd R-CHOP cycle and iPET to avoid inflammatory reactions (Eur J Nucl Med Mol Imaging 30:682, 2003), no G-CSF after the 2nd cycle to avoid altered glucose biodistribution (J Nucl Med 47:950, 2006), standardized uptake value (SUV)-based PET interpretation to improve reproducibility (favorable iPET response: reduction of maximum SUV by > 66 % compared to baseline; J Nucl Med 48:1626, 2007). Pts. with CD20+ lymphomas and a favorable iPET were randomized to receive 4 more cycles of R-CHOP or the same treatment plus 2 extra doses of R (part A of the trial). Pts. with an unfavorable iPET were randomized to continue R-CHOP for 6 additional cycles or receive 6 blocks of a more complex methotrexate-, cytarabine- and etoposide-based regimen originally designed for Burkitt lymphoma (Blood 124: 3870, 2014; part B). R was omitted in pts. with CD20- lymphomas. Sample size of the entire study population was based on the empirically derived assumption that treatment failure after 2 yrs. (TF: progression, relapse, treatment discontinuation due to toxicity, start of alternative therapy, death of any cause) could be improved from 80 % to 90 % in part A and from 30 % to 45 % in part B (alpha=0.05, power=0.8). Secondary endpoints included OS and toxicity. Results: Fifty-seven oncological centers and 23 nuclear medicine institutions participated in the trial. Between 2007 and 2012 1072 pts. were registered, and 862 (80.4 %) had a positive baseline PET, received 2 cycles R-CHOP, underwent iPET and were allocated to one of the post-iPET treatment arms detailed above. Reference pathology was available in 98 %, and median follow-up is 52 months. All in all, there were 779 patients with CD20+ aggressive B-cell lymphomas (90.4 % of all treated pts.) of whom 606 had diffuse large B-cell lymphoma (DLBCL), 42 primary mediastinal B-cell lymphoma (PMBCL) and 42 follicular lymphoma grade 3 (FL3). Interim PET was favorable in 691 pts. (88.7 %) and unfavorable in 88 pts. with CD20+ lymphomas (11.3 %). It was highly predictive of TTTF for CD20+ lymphomas in general and for each of the DLBCL, PMBCL and FL3 subgroups (Table). In CD20+ lymphomas and DLBCL, the iPET response predicted TF independently of the International Prognostic Index, and it was also predictive of OS. The groups of PMBCL and FL3 were too small for multivariate analyses. In part A, adding 2 extra doses of R failed to improve TTTF and OS in all histological entities. Separate analyses for subgroups defined by sex, age (< vs. > 60 yrs.) or a combination of the two showed no statistically significant benefit of extra doses of R in any of the subgroups. In pts. with an unfavorable iPET response, a switch from R-CHOP to the Burkitt regimen failed to improve TTTF or OS in CD20+ lymphomas in general (Figure) and in the DLBCL, PMBCL and FL3 subgroups. In part B, the Burkitt protocol was associated with more grade 3/4 leukopenia (82 % vs. 57 %, p=0.02), thrombocytopenia (59 % vs. 18 %, p=0.0001), infection (41 % vs. 16 %, p=0.017) and mucositis (39 % vs. 7 %, p=0.0007) than R-CHOP, but treatment-related mortality was similar in both arms (1 death each). Conclusion: In this large multicenter trial iPET proved highly predictive of outcome in pts. with CD20+ aggressive B-cell lymphomas, DLBCL, PMBCL or FL3 treated with R-CHOP. In pts. with a favorable iPET response, addition of 2 extra doses of R to 6 cycles R-CHOP failed to improve outcome in CD20+ lymphomas in general and in subgroups defined by histology, sex or age. In pts. with an unfavorable iPET response, switching to a more aggressive protocol also failed to improve outcome in any of the entities. Novel strategies are required for aggressive B-cell lymphomas failing to respond to the first 2 cycles of R-CHOP. Table Table. Figure Figure. Disclosures Duehrsen: Roche: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Alexion Pharmaceuticals: Honoraria, Research Funding. Giagounidis:Celgene Corporation: Consultancy. Grube:BMS, Sanofi: Consultancy. Klapper:Roche, Novartis, Amgen, Takeda: Research Funding. Hüttmann:Bristol-Myers Squibb, Takeda, Celgene, Roche: Honoraria; Gilead, Amgen: Other: Travel cost." @default.
- W4207036698 created "2022-01-26" @default.
- W4207036698 creator A5002333415 @default.
- W4207036698 creator A5003062229 @default.
- W4207036698 creator A5003253888 @default.
- W4207036698 creator A5005029408 @default.
- W4207036698 creator A5005770151 @default.
- W4207036698 creator A5005815307 @default.
- W4207036698 creator A5005879000 @default.
- W4207036698 creator A5006360930 @default.
- W4207036698 creator A5012101254 @default.
- W4207036698 creator A5013394319 @default.
- W4207036698 creator A5013949384 @default.
- W4207036698 creator A5014089754 @default.
- W4207036698 creator A5014397359 @default.
- W4207036698 creator A5020918589 @default.
- W4207036698 creator A5021658774 @default.
- W4207036698 creator A5022062256 @default.
- W4207036698 creator A5024454510 @default.
- W4207036698 creator A5025857936 @default.
- W4207036698 creator A5026601540 @default.
- W4207036698 creator A5029977875 @default.
- W4207036698 creator A5030450404 @default.
- W4207036698 creator A5032061719 @default.
- W4207036698 creator A5033302235 @default.
- W4207036698 creator A5036872888 @default.
- W4207036698 creator A5036933302 @default.
- W4207036698 creator A5038771532 @default.
- W4207036698 creator A5041248775 @default.
- W4207036698 creator A5043786373 @default.
- W4207036698 creator A5047158350 @default.
- W4207036698 creator A5049356892 @default.
- W4207036698 creator A5053157771 @default.
- W4207036698 creator A5055376168 @default.
- W4207036698 creator A5055422099 @default.
- W4207036698 creator A5056259810 @default.
- W4207036698 creator A5057105042 @default.
- W4207036698 creator A5060093906 @default.
- W4207036698 creator A5060213460 @default.
- W4207036698 creator A5060326878 @default.
- W4207036698 creator A5062881120 @default.
- W4207036698 creator A5065535410 @default.
- W4207036698 creator A5066213019 @default.
- W4207036698 creator A5070260720 @default.
- W4207036698 creator A5074160467 @default.
- W4207036698 creator A5074209268 @default.
- W4207036698 creator A5074439466 @default.
- W4207036698 creator A5078376583 @default.
- W4207036698 creator A5082867129 @default.
- W4207036698 creator A5084120623 @default.
- W4207036698 creator A5087467494 @default.
- W4207036698 creator A5090782156 @default.
- W4207036698 date "2016-12-02" @default.
- W4207036698 modified "2023-10-15" @default.
- W4207036698 title "Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with B Cell Lymphomas Participating in the PETAL Trial" @default.
- W4207036698 doi "https://doi.org/10.1182/blood.v128.22.1857.1857" @default.
- W4207036698 hasPublicationYear "2016" @default.
- W4207036698 type Work @default.
- W4207036698 citedByCount "7" @default.
- W4207036698 countsByYear W42070366982017 @default.
- W4207036698 countsByYear W42070366982018 @default.
- W4207036698 countsByYear W42070366982021 @default.
- W4207036698 countsByYear W42070366982022 @default.
- W4207036698 crossrefType "journal-article" @default.
- W4207036698 hasAuthorship W4207036698A5002333415 @default.
- W4207036698 hasAuthorship W4207036698A5003062229 @default.
- W4207036698 hasAuthorship W4207036698A5003253888 @default.
- W4207036698 hasAuthorship W4207036698A5005029408 @default.
- W4207036698 hasAuthorship W4207036698A5005770151 @default.
- W4207036698 hasAuthorship W4207036698A5005815307 @default.
- W4207036698 hasAuthorship W4207036698A5005879000 @default.
- W4207036698 hasAuthorship W4207036698A5006360930 @default.
- W4207036698 hasAuthorship W4207036698A5012101254 @default.
- W4207036698 hasAuthorship W4207036698A5013394319 @default.
- W4207036698 hasAuthorship W4207036698A5013949384 @default.
- W4207036698 hasAuthorship W4207036698A5014089754 @default.
- W4207036698 hasAuthorship W4207036698A5014397359 @default.
- W4207036698 hasAuthorship W4207036698A5020918589 @default.
- W4207036698 hasAuthorship W4207036698A5021658774 @default.
- W4207036698 hasAuthorship W4207036698A5022062256 @default.
- W4207036698 hasAuthorship W4207036698A5024454510 @default.
- W4207036698 hasAuthorship W4207036698A5025857936 @default.
- W4207036698 hasAuthorship W4207036698A5026601540 @default.
- W4207036698 hasAuthorship W4207036698A5029977875 @default.
- W4207036698 hasAuthorship W4207036698A5030450404 @default.
- W4207036698 hasAuthorship W4207036698A5032061719 @default.
- W4207036698 hasAuthorship W4207036698A5033302235 @default.
- W4207036698 hasAuthorship W4207036698A5036872888 @default.
- W4207036698 hasAuthorship W4207036698A5036933302 @default.
- W4207036698 hasAuthorship W4207036698A5038771532 @default.
- W4207036698 hasAuthorship W4207036698A5041248775 @default.
- W4207036698 hasAuthorship W4207036698A5043786373 @default.
- W4207036698 hasAuthorship W4207036698A5047158350 @default.
- W4207036698 hasAuthorship W4207036698A5049356892 @default.
- W4207036698 hasAuthorship W4207036698A5053157771 @default.
- W4207036698 hasAuthorship W4207036698A5055376168 @default.
- W4207036698 hasAuthorship W4207036698A5055422099 @default.
- W4207036698 hasAuthorship W4207036698A5056259810 @default.